{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:47:42Z","timestamp":1790207262442,"version":"4.1.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background and purpose:<\/jats:title>\n                    <jats:p>Heat shock protein 90 (Hsp90) is a molecular chaperone critical for the stabilization of numerous oncoproteins, making it a promising target for anticancer drug development. This study aimed to design, synthesize, and evaluate novel 3,5-diarylisoxazole derivatives as potential Hsp90 inhibitors<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental approach:<\/jats:title>\n                    <jats:p>\n                      A series of 3,5-diarylisoxazole compounds (5R\n                      <jats:sub>1-6<\/jats:sub>\n                      ) was designed using molecular docking to predict binding affinity. Compounds were synthesized\n                      <jats:italic toggle=\"yes\">via<\/jats:italic>\n                      cyclization of 4-chloroacetophenone with hydroxylamine hydrochloride, followed by condensation with various aldehydes. Structures were confirmed by melting point, FT-IR, and 1H-NMR spectroscopy. The MTT assay assessed cytotoxicity, and Hsp90 inhibitory activity was evaluated using an Hsp ELISA kit. The stability of the 5R3 compound in the Hsp90 active site was investigated using molecular dynamics simulation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings\/Results:<\/jats:title>\n                    <jats:p>\n                      All compounds showed favorable binding energies. Compound 5R3 showed the highest binding affinity (\u0394G = -7.83 kcal\/mol) and the highest cytotoxicity against MCF-7 cells (IC50 = 0.014 \u03bcM) and significantly reduced Hsp90 concentration from 5.54 ng\/mL (untreated) to 1.56 ng\/mL. Furthermore, molecular dynamics simulation studies confirmed the stability of the Hsp90-5R\n                      <jats:sub>3<\/jats:sub>\n                      complex during a 100 ns simulation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and implications:<\/jats:title>\n                    <jats:p>\n                      Compound 5R\n                      <jats:sub>3<\/jats:sub>\n                      with an electronegative substituent (F) on the aromatic ring showed the highest cytotoxic effect, also decreased the concentration of Hsp90 protein more than others.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/rps.rps_173_25","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:00:08Z","timestamp":1777176008000},"page":"191-205","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Design, synthesis, and biological evaluation of novel aryl isoxazoles as potential Hsp90 inhibitors"],"prefix":"10.4103","volume":"21","author":[{"given":"Mina","family":"Ardestani","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry and Pharmaceutical Sciences Research Centre, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Keshavarzipour","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Pharmaceutical Sciences Research Centre, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Abbasi","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Zarghi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science Research Center, Faculty of Pharmacy and Pharmaceutical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aghaei","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Ghiaci","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Isfahan University of Technology, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojjat","family":"Sadeghi-Aliabadi","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Pharmaceutical Sciences Research Centre, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"4","key":"R1-20260429","doi-asserted-by":"crossref","first-page":"255","DOI":"10.12965\/jer.1632642.321","article-title":"Size dependent classification of heat shock proteins: a mini-review","volume":"12","author":"Jee","year":"2016","journal-title":"J Exerc Rehabil"},{"issue":"5","key":"R2-20260429","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1152\/japplphysiol.01267.2001","article-title":"Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance","volume":"92","author":"Kregel","year":"2002","journal-title":"J Appl Physiol"},{"issue":"6","key":"R3-20260429","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrm.2017.20","article-title":"The HSP90 chaperone machinery","volume":"18","author":"Schopf","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1738","key":"R4-20260429","doi-asserted-by":"crossref","first-page":"20160527,1","DOI":"10.1098\/rstb.2016.0527","article-title":"Heat shock protein 90: its inhibition and function","volume":"373","author":"Zuehlke","year":"2018","journal-title":"Philos Trans R Soc B Biol Sci"},{"issue":"12","key":"R5-20260429","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1021\/acs.jmedchem.5b01106","article-title":"Development of heat shock protein (Hsp90) inhibitors to combat resistance to tyrosine kinase inhibitors through HSP90-kinase interactions","volume":"59","author":"Wang","year":"2016","journal-title":"J Med Chem"},{"issue":"21","key":"R6-20260429","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1021\/jm500823a","article-title":"Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors: Miniperspective","volume":"57","author":"Bhat","year":"2014","journal-title":"J Med Chem"},{"issue":"10","key":"R7-20260429","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.3390\/pharmaceutics14102220","article-title":"Heterocyclic compounds as Hsp90 inhibitors: a perspective on anticancer applications","volume":"14","author":"Ardestani","year":"2022","journal-title":"Pharmaceutics"},{"issue":"n","key":"R8-20260429","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1021\/jo4002849","article-title":"Learning from nature: advances in geldanamycin-and radicicol-based inhibitors of Hsp90","volume":"78","author":"Kitson","year":"2013","journal-title":"J Org Chem"},{"issue":"11","key":"R9-20260429","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.bmc.2016.03.049","article-title":"Synthesis and evaluation of 4-(2-hydroxypropyl) piperazin-1-yl) derivatives as Hsp90 inhibitors","volume":"24","author":"Cherfaoui","year":"2016","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"R10-20260429","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bmc.2008.11.064","article-title":"Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold","volume":"17","author":"Hadden","year":"2009","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"R11-20260429","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.bmc.2011.03.013","article-title":"Design, synthesis, and evaluation of small molecule Hsp90 probes","volume":"19","author":"Taldone","year":"2011","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"R12-20260429","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1389450120666190829162544","article-title":"Recent advances in the discovery of novel HSP90 inhibitors: an update from 2014","volume":"21","author":"Xiao","year":"2020","journal-title":"Curr Drug Targets"},{"issue":"4","key":"R13-20260429","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1158\/1535-7163.MCT-07-0149","article-title":"Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole\/isoxazole amide analogues","volume":"6","author":"Sharp","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"R14-20260429","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/14756366.2018.1504041","article-title":"Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents","volume":"33","author":"\u00c7al\u0131\u015fkan","year":"2018","journal-title":"J Enzyme Inhib Med Chem"},{"key":"R15-20260429","doi-asserted-by":"crossref","first-page":"111699","DOI":"10.1016\/j.ejmech.2019.111699","article-title":"Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (HSP90) inhibitors with significant anti-HIV activity","volume":"183","author":"Trivedi","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"2","key":"R16-20260429","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/jm701018h","article-title":"4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer","volume":"51","author":"Brough","year":"2008","journal-title":"J Med Chem"},{"issue":"12","key":"R17-20260429","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1080\/07391102.2019.1660216","article-title":"New heat shock protein (Hsp90) inhibitors, designed by pharmacophore modeling and virtual screening: synthesis, biological evaluation and molecular dynamics studies","volume":"38","author":"Abbasi","year":"2020","journal-title":"J Biomol Struct Dyn"},{"issue":"1","key":"R18-20260429","doi-asserted-by":"crossref","first-page":"28017","DOI":"10.1038\/s41598-024-79051-5","article-title":"Design, synthesis and biological studies of new isoxazole compounds as potent Hsp90 inhibitors","volume":"14","author":"Keshavarzipour","year":"2024","journal-title":"Scientific Reports"},{"issue":"16","key":"R19-20260429","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J Comput Chem"},{"issue":"7","key":"R21-20260429","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jmgm.2009.12.007","article-title":"Molecular modeling of Helicobacter pylori arginase and the inhibitor coordination interactions","volume":"28","author":"Azizian","year":"2010","journal-title":"J Mol Graph Model"},{"issue":"5","key":"R22-20260429","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1021\/ci400071x","article-title":"Molecular dynamics simulation by GROMACS using GUI plugin for PyMOL","volume":"53","author":"Makarewicz","year":"2013","journal-title":"J Chem Inf Model"},{"issue":"5","key":"R23-20260429","doi-asserted-by":"crossref","first-page":"109,1","DOI":"10.1007\/s00894-016-2982-4","article-title":"Improvements in GROMACS plugin for PyMOL, including implicit solvent simulations and displaying results of PCA analysis","volume":"22","author":"Makarewicz","year":"2016","journal-title":"J Mol Model"},{"issue":"7","key":"R24-20260429","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","article-title":"GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit","volume":"29","author":"Pronk","year":"2013","journal-title":"Bioinformatics"},{"issue":"7","key":"R25-20260429","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1021\/ct200133y","article-title":"Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values","volume":"7","author":"S\u2298ndergaard","year":"2011","journal-title":"J Chem Theory Comput"},{"key":"R26-20260429","first-page":"367,1","article-title":"Vranken","volume":"5","author":"Sousa da","year":"2012","journal-title":"ACPYPE-Antechamber Python parser interface. BMC Res Notes"},{"issue":"7","key":"R27-20260429","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/ph15070820","article-title":"4-Substituted thieno [3, 2-d] pyrimidines as dual-stage antiplasmodial derivatives","volume":"15","author":"Lagard\u00e8re","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"7","key":"R28-20260429","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1055\/s-0029-1219575","article-title":"Metal-free one-pot conversion of electron-rich aromatics into aromatic nitriles","volume":"2010","author":"Ushijima","year":"2010","journal-title":"Synlett"},{"issue":"2","key":"R29-20260429","first-page":"171","article-title":"A reliable synthesis of 3-amino-5-alkyl and 5-amino-3-alkyl isoxazoles","volume":"45","author":"Johnson","year":"2013","journal-title":"Synthesis (Stuttg)"},{"issue":"5","key":"R30-20260429","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/1735-5362.268201","article-title":"Synthesis and cytotoxic evaluation of some quinazolinone-5-(4- chlorophenyl) 1, 3, 4-oxadiazole conjugates","volume":"14","author":"Hassanzadeh","year":"2019","journal-title":"Res Pharm Sci"},{"issue":"6","key":"R31-20260429","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4103\/1735-5362.327509","article-title":"Synthesis and cytotoxic activity evaluation of some new 1, 3, 4-oxadiazole, 1, 3, 4- thiadiazole and 1, 2, 4- triazole derivatives attached to phthalimide","volume":"16","author":"Hsanzadeh","year":"2021","journal-title":"Res Pharm Sci"},{"issue":"18","key":"R32-20260429","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2174\/1871520621666210201101818","article-title":"Identification of new Hsp90 inhibitors: structure based virtual screening, molecular dynamic simulation, synthesis and biological evaluation","volume":"21","author":"Abbasi","year":"2021","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"R33-20260429","first-page":"119","article-title":"\u00dcber die Einwirkung von Halogenphosphor auf Alkyl-formanilide","volume":"60","author":"Vilsmeier","year":"1927","journal-title":"Eine neue Methode zur Darstellung sekund\u00e4rer und terti\u00e4rer p-Alkylamino-benzaldehyde. Ber Dtsch Chem Ges"},{"issue":"6","key":"R34-20260429","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1007\/s11696-021-01775-9","article-title":"The inhibitory potency of isoxazole-curcumin analogue for the management of breast cancer: a comparative in vitro and molecular modeling investigation","volume":"75","author":"Rodrigues","year":"2021","journal-title":"Chem Pap"},{"issue":"9","key":"R35-20260429","doi-asserted-by":"crossref","first-page":"662","DOI":"10.2174\/1568026619666190305124954","article-title":"Synthesis, screening and docking analysis of Hispolon pyrazoles and isoxazoles as potential antitubercular agents","volume":"19","author":"Balaji","year":"2019","journal-title":"Curr Top Med Chem"},{"issue":"12","key":"R36-20260429","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3390\/molecules22122077","article-title":"An isoxazole chalcone derivative enhances melanogenesis in B16 melanoma cells via the Akt\/GSK3\u03b2\/\u03b2-catenin signaling pathways","volume":"22","author":"Yin","year":"2017","journal-title":"Molecules"},{"issue":"3","key":"R37-20260429","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/japtr.japtr_170_23","article-title":"Molecular modeling, synthesis, and antiproliferative evaluation of new isoxazole ring linked by Schiff bases and azo bond","volume":"14","author":"Taha","year":"2023","journal-title":"J Adv Pharm Technol Res"},{"key":"R38-20260429","doi-asserted-by":"crossref","first-page":"103433","DOI":"10.1016\/j.bioorg.2019.103433","article-title":"Discovery of 5-aryl-3-thiophen-2-yl-1H- pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma","volume":"94","author":"Mohamady","year":"2020","journal-title":"Bioorganic Chem"},{"key":"R39-20260429","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/jhet.70073","article-title":"Recent development in synthesis and anticonvulsant activity of promising Schiff base derivatives","volume":"62","author":"Ngu","year":"2025","journal-title":"J Heterocyclic Chem"},{"issue":"9","key":"R40-20260429","first-page":"1495","article-title":"6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib- sensitive and -resistant tumor cell lines","volume":"8","author":"Hamed","year":"2013","journal-title":"J Med Chem"},{"issue":"12","key":"R41-20260429","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.3390\/molecules28124766","article-title":"Synthesis, crystal structure, D F T, and anticancer activity of some imine-type compounds via routine Schiff base reaction: an example of unexpected cyclization to oxazine derivative","volume":"28","author":"Lasri","year":"2023","journal-title":"Molecules"},{"issue":"2","key":"R42-20260429","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3390\/ijms12020946","article-title":"Structural determi nation of three different series of compounds as Hsp90 inhibitors using 3D-QSAR modeling, molecular docking and molecular dynamics methods","volume":"12","author":"Liu","year":"2011","journal-title":"Int J Mol Sci"},{"key":"R43-20260429","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molstruc.2019.04.082","article-title":"New thiosemicarbazide-1,2,3-triazole hybrids as potent \u03b1-glucosidase inhibitors: design, synthesis, and biological evaluation","volume":"1192","author":"Bakherad","year":"2019","journal-title":"J Mol Struct"},{"key":"R44-20260429","first-page":"100938","article-title":"Design, synthesis and biological evaluation of isoxazole bearing N-arylpyrazole derivatives as anticancer agents","volume":"41","author":"Chandavaram","year":"2022","journal-title":"Chem Data Coll"},{"issue":"4","key":"R45-20260429","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1158\/1535-7163.MCT-07-0149","article-title":"Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole\/isoxazole amide analogues","volume":"6","author":"Sharp","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"R46-20260429","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1016\/j.bmcl.2015.06.009","article-title":"Synthesis and biological evaluation of 3,5- disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors","volume":"25","author":"Sun","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"R47-20260429","first-page":"113383","article-title":"Advances in Hsp90 inhibitors for cancer therapy","volume":"218","author":"Wang","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"4","key":"R48-20260429","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4103\/RPS.RPS_159_23","article-title":"Gold nanoparticles from Artemisia absinthium, Morus nigra, and Peganum harmala: biosynthesis, characterization, and their biological evaluations against cancer cells","volume":"20","author":"Sadeghi-Aliabadi","year":"2025","journal-title":"Res Pharm Sci"}],"container-title":["Research in Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/RPS.RPS_173_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:03:06Z","timestamp":1786647786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/RPS.RPS_173_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/rps.rps_173_25","relation":{},"ISSN":["1735-5362","1735-9414"],"issn-type":[{"value":"1735-5362","type":"print"},{"value":"1735-9414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-09-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}